Check 35,000+ stocks against 26 valuation models and 37 quality factors

China Regenerative Medicine International Ltd (8158) fair value: what the stock is really worth

We calculate from audited financials what China Regenerative Medicine International Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · ISIN KYG2129W1125

CR Thin data Sep 13, 2026

China Regenerative Medicine International Ltd

8158 · HK

Clearly undervaluedStrong Fair Value upside, but quality is only moderate.

✓Fair value HK$0.7200 · Strongly undervalued (+172%)

!Quality 57/100

!Weak Growth (revenue 5y −16.9 %/yr)

✓Highly profitable · 38.2% net margin (TTM)

✓Low debt · generates free cash flow

✓Ranks above peers (11/12)

!Moderate moat 61/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear HK$0.6200 to bull HK$0.9000 Growth analysisrevenue history, year by year Quality 57/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch China Regenerative Medicine International Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range HK$0.0940 – HK$4.60 · fair‑value band HK$0.6200 – HK$0.9000 · the HK$0.2650 price screens below the HK$0.7200 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

China Regenerative Medicine International Limited, together with its subsidiaries, engages in the research, development, production, and sale of tissue engineering and regenerative medicine products in Hong Kong and China. It operates in two segments, Aesthetic Medical and Beauty Services, and Medical Services. The company offers anti-aging /prevention, functional medicine and solutions, and treatment and diagnosis; hair regenerating medical solutions; and zoom consultation, mental fog therapy, physiotherapy, acnes treatment, and facial and slimming acupuncture services. It also provides skin regeneration, body function refining, Chinese/medical aesthetics, slimming and detoxing, and uterine and circulation services; endoscopy and scar removal services; and medical tests and vaccines. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in February 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Tsim Sha Tsui, Hong Kong.

Stock analysis

China Regenerative Medicine International Ltd (8158) currently trades at HK$0.2650, while our model-based Fair Value estimate is HK$0.7200, implying the stock looks roughly 63.2% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$4.20 per share, and 14 of the 23 models we run sit above the HK$0.2650 price.

Bear case: the Asset-Based group reads lowest at HK$0.1200, and 9 of the 23 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$0.6200 (bear) to HK$0.9000 (bull), the price of HK$0.2650 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

China Regenerative Medicine International Ltd reported revenue of HK$72.1M in FY2025 versus HK$283M in FY2021, a compound −29.0%/yr. Reported net income was HK$27.5M in FY2025, compounding −14.6%/yr from FY2021.

Key figures

Market cap HK$80.6M (≈ $10.3M) · P/E ratio 3.1 · P/S ratio 1.19 · EPS (TTM) HK$0.0200 · Dividend yield 1.6% · Net margin 38.2% · Return on equity 70.0% · Return on assets (EBIT) −3.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 78% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 172%, 8158 screens cheaper than that median.

Fair Value models

Bear HK$0.6200 Fair Value HK$0.7200 Bull HK$0.9000

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0143 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$0.1000 HK$0.1600 HK$0.3400 73

Growth DCF HK$0.0900 HK$0.1800 HK$0.3200 73

Owner Earnings HK$1.30 HK$2.62 HK$4.92 70

All 23 models by family

DCF Models

FCF DCF HK$0.1000 HK$0.1600 HK$0.3400 73

Owner Earnings HK$1.30 HK$2.62 HK$4.92 70

5Y Revenue Exit HK$0.0800 HK$0.1700 HK$0.3700 65

5Y EBITDA Exit HK$0.1800 HK$0.3800 HK$0.7600 68

5Y P/E Exit HK$0.9600 HK$2.49 HK$4.62 64

10Y Revenue Exit HK$0.0800 HK$0.2300 HK$0.3200 63

10Y EBITDA Exit HK$0.1500 HK$0.4100 HK$0.8800 60

10Y P/E Exit HK$0.6400 HK$1.84 HK$3.92 56

Earnings-Based

Graham-Dodd HK$0.6200 HK$4.29 HK$6.02 61

Lynch FV HK$2.22 HK$3.17 HK$4.12 59

PEG = 1.0 HK$2.22 HK$3.17 HK$4.12 55

Dividend Discount

Gordon GGM HK$0.0300 HK$0.0500 HK$0.0700 66

DDM Multi-Stage HK$0.0300 HK$0.0500 HK$0.0600 65

Multiples

P/E Multiple HK$1.49 HK$1.99 HK$2.49 63

P/S Multiple HK$0.6200 HK$0.8300 HK$1.04 58

P/B Multiple HK$0.5900 HK$0.7900 HK$0.9900 55

EV/EBITDA HK$0.2300 HK$0.3200 HK$0.4200 67

EV/Revenue HK$0.0600 HK$0.1100 HK$0.1600 52

Asset-Based

NCAV (Graham) HK$0.0900 HK$0.1200 HK$0.1800 54

Growth DCF

Growth DCF HK$0.0900 HK$0.1800 HK$0.3200 73

Rev-Margin DCF HK$0.0900 HK$0.2100 HK$0.4500 64

Economic Profit

Residual Income HK$0.7200 HK$1.39 HK$34.03 61

Growth Earnings

Growth-Adj P/E HK$2.94 HK$4.20 HK$5.46 65

Open the full fair value analysis →

Notify me when 8158 reaches fair value

Put 8158 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 57/100

Of which business quality 53 · Market factors (momentum, volatility) 25

Profitability 73

Margins and returns on capital today

Quality Growth 17

Are margins and returns improving?

Cashflow 42

Earnings quality: real cash, not paper profit

Fin. Strength 32

Balance sheet, leverage, solvency risk

Investment 100

Disciplined investing over empire-building

Low Volatility 50

Calm price path (market factor)

Momentum 22

Price trend over the last 3–12 months (market factor)

52W Momentum 1

Distance to the 52-week high (market factor)

Net Issuance 71

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

−20.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+20.2%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−16.9%

Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+5.7%

’12

’14

’15

’16

’17

’18

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+15.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year+14.1%

Dividend (yield on the price)1.6%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−23% → −2%

2025 sits 144% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

A lot of optimism in the price

The price assumes more growth than the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+15.5%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

Watch 8158, get fair value alerts →

Compare China Regenerative Medicine International Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 646 stocks

Beats the industry median on 11/12 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 57 · Above median

Profitability

Return on equity (TTM) 70% · Top 25%

Return on assets 0% · Above median

Net margin (TTM) 38% · Top 25%

Operating margin (TTM) 6% · Above median

Growth and dividend

Revenue growth 45% · Top 25%

Dividend yield (TTM) 1.6% · Above median

Balance sheet

Debt / equity 0.50× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 3.1× · Cheapest 25%

P/B 1.59× · Cheaper than median

P/S (TTM) 1.18× · Cheapest 25%

P/FCF 2.7× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)100 · sector 0

FUTURE (revenue growth)100 · sector 0

PAST (return on equity)100 · sector 0

HEALTH (low debt)75 · sector 97

DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$514.63	$566.09	+10%
Regeneron Pharmaceuticals, Inc REGN	$774.11	$1,241	+60%
argenx SE ARGX	$984.69	$917.18	−7%
BeOne Medicines AG 688235	¥247.30	¥124.62	−50%
Samsung Biologics Co 207940	1,396,000 KRW	1,535,600 KRW	+10%
CSL Limited CSL	A$174.41	A$191.85	+10%
Alnylam Pharmaceuticals, Inc ALNY	$238.27	$211.88	−11%
Royalty Pharma plc RPRX	$58.47	$24.22	−59%
Celltrion, Inc 068270	180,300 KRW	74,519 KRW	−59%
BioNTech SE BNTX	$96.69	$62.63	−35%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

China Regenerative Medicine International Ltd · Fair Value
HK$0.7200 +63%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/8158" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">China Regenerative Medicine International Ltd · Fair Value</span><br><b style="font-size:20px">HK$0.7200</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+63%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "China Regenerative Medicine International Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8158

Frequently asked questions

Is China Regenerative Medicine International Ltd (8158) overvalued or undervalued?

As of Sep 13, 2026, our model estimates a fair value of HK$0.7200 versus a price of HK$0.2650, about +172% upside (undervalued).

What is the fair value of 8158?

Our model-based fair value for China Regenerative Medicine International Ltd is HK$0.7200 (as of Sep 13, 2026), built from audited fundamentals. The current price: HK$0.2650.

What is the quality score of 8158?

China Regenerative Medicine International Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for China Regenerative Medicine International Ltd (8158)?

Our model-based price target is the fair value of HK$0.7200 (as of Sep 13, 2026) from 23 valuation models. Cautious scenario HK$0.6200, optimistic scenario HK$0.9000. It is a calculation from audited fundamentals, not an analyst target.

What is the China Regenerative Medicine International Ltd stock forecast for 2026?

Our models put fair value at HK$0.7200, about +172% upside versus a price of HK$0.2650 (undervalued). Cautious scenario HK$0.6200, optimistic scenario HK$0.9000. The calculation is refreshed regularly with new filings.

What is the revenue of China Regenerative Medicine International Ltd (8158)?

China Regenerative Medicine International Ltd reported trailing-twelve-month revenue of about HK$72.1M (latest available figure, as of Sep 13, 2026).

Does China Regenerative Medicine International Ltd pay a dividend?

China Regenerative Medicine International Ltd currently shows a dividend yield of about 1.60% relative to its recent price (as of Sep 13, 2026).

What growth is priced into China Regenerative Medicine International Ltd (8158)?

For today's price to be fair in a discounted-cash-flow model, China Regenerative Medicine International Ltd would have to grow free cash flow by +15.5 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -16.9 % per year. As of Sep 13, 2026.

What discount rate (WACC) does the fair value of 8158 use?

Our models discount China Regenerative Medicine International Ltd at 10.3 %: a base by market capitalisation (nano), country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For China Regenerative Medicine International Ltd that is +15.5 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.

How much growth has China Regenerative Medicine International Ltd (8158) delivered so far?

Over the past 5 years revenue at China Regenerative Medicine International Ltd grew -16.9 % a year. The price currently implies +15.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of China Regenerative Medicine International Ltd (8158) growing?

The median revenue growth in the sector is +4.4 % a year. That is the yardstick for the growth priced into China Regenerative Medicine International Ltd (+15.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of China Regenerative Medicine International Ltd (8158)?

The free-cash-flow yield on the price is 4.99 %: that much free cash flow China Regenerative Medicine International Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of China Regenerative Medicine International Ltd (8158)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For China Regenerative Medicine International Ltd it is HK$0.7200 per share (as of Sep 13, 2026), against a price of HK$0.2650. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).

Is China Regenerative Medicine International Ltd stock overvalued or undervalued in 2026?

As of Sep 13, 2026, 8158 trades below its calculated fair value: price HK$0.2650, fair value HK$0.7200, a gap of about +172% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 8158?

No. The price is what the market pays today (HK$0.2650); the fair value is what the company's own numbers justify (HK$0.7200). For China Regenerative Medicine International Ltd the two are HK$0.4550 per share apart. That gap is exactly why we show both numbers side by side.

How much is China Regenerative Medicine International Ltd worth?

The market values China Regenerative Medicine International Ltd at about HK$80.6M (market capitalisation, as of Sep 13, 2026). Per share that is HK$0.2650; our models calculate a fair value of HK$0.7200 per share.

What do the bullish and bearish scenarios say about 8158?

Our models span a range for China Regenerative Medicine International Ltd: cautious scenario HK$0.6200, base HK$0.7200, optimistic HK$0.9000 per share (as of Sep 13, 2026, price HK$0.2650). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 8158?

China Regenerative Medicine International Ltd trades at a price-to-earnings ratio of 3.1 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.7200 is built from several models across several years. Other multiples: P/B 1.6, P/S 1.2.

How solid is the balance sheet of China Regenerative Medicine International Ltd (8158)?

Balance-sheet figures for China Regenerative Medicine International Ltd (as of Sep 13, 2026): return on equity 70.0%, debt of 0.50 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.

How far is 8158 from its 52-week high?

China Regenerative Medicine International Ltd trades at HK$0.2650, about 78% below its 52-week high of HK$1.20 and 10% above the low of HK$0.2400 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.7200 is for.

Which stocks are comparable to China Regenerative Medicine International Ltd?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is China Regenerative Medicine International Ltd stock attractive at the current price?

The data as of Sep 13, 2026: price HK$0.2650, calculated fair value HK$0.7200 (+172%), Quality Score 57/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 8158 calculated?

We run China Regenerative Medicine International Ltd through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.7200, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 15.5 % above its aggregate fair value. China Regenerative Medicine International Ltd currently trades 172 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of China Regenerative Medicine International Ltd (8158)?

The closing price on Sep 17, 2026 was HK$0.2650. Our model-based fair value is HK$0.7200, about +172% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with China Regenerative Medicine International Ltd right now?

The price is below even our cautious bear case (HK$0.6200). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of China Regenerative Medicine International Ltd

How large is the market capitalisation of China Regenerative Medicine International Ltd (8158)?

The market capitalisation of China Regenerative Medicine International Ltd is HK$80.6M (≈ $10.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of China Regenerative Medicine International Ltd (8158)?

The price-to-sales ratio of China Regenerative Medicine International Ltd is 1.19 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of China Regenerative Medicine International Ltd (8158)?

Earnings per share at China Regenerative Medicine International Ltd are HK$0.0200 (price ÷ EPS = P/E 3.1). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of China Regenerative Medicine International Ltd (8158)?

The dividend yield of China Regenerative Medicine International Ltd is 1.6% (payout 21.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of China Regenerative Medicine International Ltd (8158)?

The net margin of China Regenerative Medicine International Ltd is 38.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of China Regenerative Medicine International Ltd (8158)?

The return on equity (ROE) of China Regenerative Medicine International Ltd is 70.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of China Regenerative Medicine International Ltd (8158)?

On an EBIT basis the return on assets of China Regenerative Medicine International Ltd is −3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of China Regenerative Medicine International Ltd (8158)?

The operating margin of China Regenerative Medicine International Ltd is 5.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at China Regenerative Medicine International Ltd (8158)?

Revenue at China Regenerative Medicine International Ltd is growing +44.9% versus a year earlier (3y avg +20.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at China Regenerative Medicine International Ltd (8158)?

Earnings per share at China Regenerative Medicine International Ltd are growing +24.1% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does China Regenerative Medicine International Ltd (8158) carry?

The net debt of China Regenerative Medicine International Ltd is HK$43.1M (fiscal year 2025, ≈ 10.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch China Regenerative Medicine International Ltd in the live analysis

One click puts China Regenerative Medicine International Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.